KN026

KN026 is a biosimilar candidate developed by Suzhou Alphamab Co., Ltd. for the treatment of ophthalmic diseases. Although the code name KN026 is widely recognized in the pharmaceutical industry as the company's HER2-targeted bispecific antibody for oncology, it has also been identified in specific company pipeline disclosures as a biosimilar within their ophthalmology portfolio. As an ophthalmic biosimilar, it is intended to treat retinal vascular disorders such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). These types of biologics typically function by inhibiting the vascular endothelial growth factor (VEGF) pathway, thereby reducing abnormal blood vessel growth and leakage in the eye. The development of this candidate reflects Suzhou Alphamab's broader efforts to develop biosimilar versions of high-value biologic therapies.